James R. Tobin, Former CEO of Boston Scientific, Joins Xenter, Inc. Board of Directors to Assist in Advance of Device/Data/Drug Technologies
Prior to joining Xenter, Tobin served as President and Chief Executive Officer of Boston Scientific from March 1999 to July 2009, during which time the company’s revenues grew from more than $2 billion to more than $8 billion.
Medtronic Receives FDA Approval to Launch Clinical Study for Implantable Tibial Neuromodulation Therapy for Bladder Incontinence
The TITAN 1 Feasibility Study is a prospective, multicenter, feasibility study to characterize the procedure for the implantable TNM device in subjects with bladder incontinence.
Fractyl Announces FDA Breakthrough Device Designation for Revita® DMR in Insulin-Treated Type 2 Diabetes
Breakthrough Designation provides recognition from the FDA of the potential value that Revita DMR can bring to patients and an opportunity for accelerated access for patients who need better treatment options.”
Analytica Announces Expansion of Enhanced Infusion System into Middle East
The EIS technology was developed by Analytica under the project names AutoStart and AutoFlush and has been sold in Australia with the trade name FirstFlow™,¹ under limited license.
Christine Lind Appointed VP of Commercial NDA Group
Christine Lind has 20 years’ experience in a variety of roles within the Life Science sector.